急性心肌梗死合并慢性肾脏病:2010至2022年全国队列研究的管理与结局
该研究基于丹麦全国医疗登记数据,纳入2010至2022年首次急性心肌梗死住院的≥18岁患者,比较合并与不合并CKD患者接受指南导向管理的概率及死亡风险。结果显示CKD患者接受冠状动脉造影、血运重建、双联抗血小板及降脂治疗的概率均较低,1年死亡率较高,但研究期间两组指南管理使用率和生存率均改善。
要点
- CKD患者接受指南导向管理(冠脉造影、血运重建、双联抗血小板、降脂)的概率显著低于无CKD患者。
- CKD患者心肌梗死后1年死亡率高于无CKD患者(21% vs 16.4%)。
- 研究期间两组指南管理使用率和生存率均呈改善趋势,但CKD相关差距持续存在。
核心结论
- 尽管所有心肌梗死患者生存率改善,CKD仍与较低的指南导向管理使用率和较高的死亡率相关。
研究设计与样本
- 基于丹麦全国医疗登记数据的回顾性队列研究,纳入2010至2022年首次急性心肌梗死住院的≥18岁患者,共21,009例,中位年龄72岁,61%为男性,中位eGFR 82 ml/min per 1.73 m2,21%合并CKD(定义eGFR <60 ml/min per 1.73 m2)。
主要发现
- 合并与不合并CKD患者30天冠状动脉造影概率分别为71%(95%CI 69%-72%)和78%(95%CI 77%-79%),P < 0.001。
- 合并与不合并CKD患者30天血运重建概率分别为52%(95%CI 50%-54%)和58%(95%CI 58%-59%),P < 0.001。
- 合并与不合并CKD患者双联抗血小板治疗概率分别为67%(95%CI 65%-68%)和70%(95%CI 69%-71%),P = 0.001。
- 合并与不合并CKD患者降脂治疗概率分别为76%(95%CI 75%-78%)和82%(95%CI 81%-83%),P < 0.001。
- 合并与不合并CKD患者1年死亡率分别为21%(95%CI 20%-22%)和16.4%(95%CI 16%-17%)。
关键数值与推荐
- CKD定义为eGFR <60 ml/min per 1.73 m2。
- 研究期间冠状动脉造影、血运重建、双联抗血小板及降脂治疗概率的上升趋势P值分别为0.05、0.03、0.02和0.03。
- 研究期间两组死亡率下降趋势P值分别为0.03和0.01。
临床怎么用
- 对合并CKD的急性心肌梗死患者,应关注指南导向管理(包括冠脉造影、血运重建、双联抗血小板和降脂治疗)的使用不足,并评估其与预后差异的关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Retrospective study of guideline-directed management of myocardial infarction in patients with and without CKD from 2010 to 2022. CKD was associated with lower rate of guideline-directed management and worse prognosis. Uptake of guideline-directed management increased and prognosis improved in both groups during the study period. BACKGROUND: CKD is present in >30% of patients with acute myocardial infarction (MI) and has been associated with lower rates of guideline-directed management and worse prognosis. We investigated the use of guideline-directed management and mortality risk in patients with and without CKD. METHODS: A nationwide cohort study based on health care registers encompassing all patients ≥18 years hospitalized with first-time MI in Denmark from 2010 to 2022 was conducted. CKD was defined as an eGFR <60 ml/min per 1.73 m2. Probability of guideline-directed management and risk of all-cause mortality in patients with and without CKD were calculated from adjusted multivariable logistic and Cox regression models with probabilities and risks standardized to the distribution of confounders in the population. RESULTS: In total, we identified 21,009 patients who met eligibility criteria. The median age was 72 years, and 61% of patients were male; the median eGFR was 82 ml/min per 1.73 m2, and 21% of patients had CKD. The 30-day probabilities of coronary angiography and revascularization were 71% (95% confidence interval [CI], 69% to 72%) and 78% (95% CI, 77% to 79%), P < 0.001 and 52% (95% CI, 50% to 54%) and 58% (95% CI, 58% to 59%), P < 0.001, in patients with and without CKD, respectively. Probabilities increased during the study period (P for trend 0.05, 0.03, 0.02, and 0.03, respectively). In patients with and without CKD, the probability of dual antiplatelet therapy was 67% (95% CI, 65% to 68%) and 70% (95% CI, 69% to 71%), P = 0.001, whereas the probability of lipid-lowering treatment was 76% (95% CI, 75% to 78%) and 82% (95% CI, 81% to 83%), P < 0.001, respectively. The associated 1-year mortality was 21% (95% CI, 20% to 22%) and 16.4% (95% CI, 16% to 17%) in patients with and without CKD, respectively. with decreasing mortality rates in both groups during the study period (P for trend 0.03 and 0.01). CONCLUSIONS: Although survival after MI improved for all patients, CKD continued to be associated with lower use of guideline-directed management and higher mortality.
引用
- Freese Ballegaard EL, Lerkevang Grove E, Kamper AL, et al. Acute Myocardial Infarction and Chronic Kidney Disease: A Nationwide Cohort Study on Management and Outcomes from 2010 to 2022. Clin J Am Soc Nephrol. 2024. PMID: 39024026. doi:10.2215/CJN.0000000000000519
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。